Advertisement
Pancreas| Volume 161, ISSUE 4, P930-938, April 2017

A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer

Published:December 05, 2016DOI:https://doi.org/10.1016/j.surg.2016.09.038

      Background

      The relationship between myopenia, nutritional status, and long-term oncologic outcomes remains poorly characterized in patients with clinically resectable pancreatic cancer. We sought to reliably quantify prognostic indicators of preoperative cachexia in a manner applicable to any clinical setting.

      Methods

      Preoperative computed tomographies were available electronically and suitable for analysis in 73 of 82 consecutive patients with pancreatic cancer undergoing pancreatoduodenectomy between November 2010 and February 2014. The psoas index was computed from the cross-sectional area of the psoas muscles normalized to vertebral body area at the third lumbar vertebra. Correlation and proportional hazards analyses were performed to identify relationships between muscularity, preoperative nutritional markers, clinicopathologic parameters, and long-term survival.

      Results

      The psoas index correlated strongly with preoperative hemoglobin and albumin levels (P = .001 and .014, respectively) identifying a pattern of preoperative frailty. High psoas index and the albumin and hemoglobin levels were associated with improved long-term survival (hazard ratio 0.014, P < .001; hazard ratio 0.43, P < .001; and hazard ratio = 0.80, P = .014); however, on multivariate analysis, the psoas index proved to be the only independent predictor of survival (hazard ratio 0.021; P = .003). Rapid decreases in the psoas index during neoadjuvant chemotherapy were associated with poor postoperative outcomes, as were decreases in the psoas index during the postoperative period.

      Conclusion

      The data indicate that the psoas index, a calculation derived from a clinically mandated, preoperative computed tomography, is a statistically powerful and easily calculated predictor of survival in pancreatic cancer when compared to tumor grade and stage as well as previously validated nutritional parameters.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rahib L.
        • Smith B.D.
        • Aizenberg R.
        • Rosenzweig A.B.
        • Fleshman J.M.
        • Matrisian L.M.
        Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
        Cancer Res. 2014; 74: 2913-2921
        • Hishinuma S.
        • Ogata Y.
        • Tomikawa M.
        • Ozawa I.
        • Hirabayashi K.
        • Igarashi S.
        Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings.
        J Gastrointest Surg. 2006; 10: 511-518
        • Ansari D.
        • Rosendahl A.
        • Elebro J.
        • Andersson R.
        Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.
        Br J Surg. 2011; 98: 1041-1055
        • Cleary S.P.
        • Gryfe R.
        • Guindi M.
        • Greig P.
        • Smith L.
        • Mackenzie R.
        • et al.
        Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
        J Am Coll Surg. 2004; 198: 722-731
        • Qin R.
        • Smyrk T.C.
        • Reed N.R.
        • Schmidt R.L.
        • Schnelldorfer T.
        • Chari S.T.
        • et al.
        Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1alpha pathway to predict survival in resectable pancreatic cancer.
        Br J Cancer. 2015; 112: 514-522
        • Wu N.
        • Chen G.
        • Hu H.
        • Pang L.
        • Chen Z.
        Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas.
        Nutr Cancer. 2015; 67: 481-485
        • Park J.W.
        • Jang J.Y.
        • Kim E.J.
        • Kang M.J.
        • Kwon W.
        • Chang Y.R.
        • et al.
        Effects of pancreatectomy on nutritional state, pancreatic function and quality of life.
        Br J Surg. 2013; 100: 1064-1070
        • La Torre M.
        • Ziparo V.
        • Nigri G.
        • Cavallini M.
        • Balducci G.
        • Ramacciato G.
        Malnutrition and pancreatic surgery: prevalence and outcomes.
        J Surg Oncol. 2013; 107: 702-708
        • Tu M.Y.
        • Chien T.W.
        • Chou M.T.
        Using a nutritional screening tool to evaluate the nutritional status of patients with colorectal cancer.
        Nutr Cancer. 2012; 64: 323-330
        • Poziomyck A.K.
        • Weston A.C.
        • Lameu E.B.
        • Cassol O.S.
        • Coelho L.J.
        • Moreira L.F.
        Preoperative nutritional assessment and prognosis in patients with foregut tumors.
        Nutr Cancer. 2012; 64: 1174-1181
        • Fearon K.
        • Arends J.
        • Baracos V.
        Understanding the mechanisms and treatment options in cancer cachexia.
        Nat Rev Clin Oncol. 2013; 10: 90-99
        • Judge S.M.
        • Wu C.L.
        • Beharry A.W.
        • Roberts B.M.
        • Ferreira L.F.
        • Kandarian S.C.
        • et al.
        Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.
        BMC Cancer. 2014; 14: 997
        • Malietzis G.
        • Johns N.
        • Al-Hassi H.O.
        • Knight S.C.
        • Kennedy R.H.
        • Fearon K.C.
        • et al.
        Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer.
        Ann Surg. 2016; 263: 320-325
        • Johns N.
        • Hatakeyama S.
        • Stephens N.A.
        • Degen M.
        • Degen S.
        • Frieauff W.
        • et al.
        Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle.
        PLoS One. 2014; 9: e83618
        • Blum D.
        • Stene G.B.
        • Solheim T.S.
        • Fayers P.
        • Hjermstad M.J.
        • Baracos V.E.
        • et al.
        Validation of the consensus-definition for cancer cachexia and evaluation of a classification model–a study based on data from an international multicentre project (EPCRC-CSA).
        Ann Oncol. 2014; 25: 1635-1642
        • Fearon K.C.
        • Baracos V.E.
        Cachexia in pancreatic cancer: new treatment options and measures of success.
        HPB (Oxford). 2010; 12: 323-324
        • Wigmore S.J.
        • Plester C.E.
        • Richardson R.A.
        • Fearon K.C.
        Changes in nutritional status associated with unresectable pancreatic cancer.
        Br J Cancer. 1997; 75: 106-109
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Bassi C.
        • Dervenis C.
        • Butturini G.
        • Fingerhut A.
        • Yeo C.
        • Izbicki J.
        • et al.
        Postoperative pancreatic fistula: an international study group (ISGPF) definition.
        Surgery. 2005; 138: 8-13
        • Sheetz K.H.
        • Zhao L.
        • Holcombe S.A.
        • Wang S.C.
        • Reddy R.M.
        • Lin J.
        • et al.
        Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer.
        Dis Esophagus. 2013; 26: 716-722
        • Sabel M.S.
        • Terjimanian M.
        • Conlon A.S.
        • Griffith K.A.
        • Morris A.M.
        • Mulholland M.W.
        • et al.
        Analytic morphometric assessment of patients undergoing colectomy for colon cancer.
        J Surg Oncol. 2013; 108: 169-175
        • Peng P.
        • Hyder O.
        • Firoozmand A.
        • Kneuertz P.
        • Schulick R.D.
        • Huang D.
        • et al.
        Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma.
        J Gastrointest Surg. 2012; 16: 1478-1486
        • Sabel M.S.
        • Lee J.
        • Cai S.
        • Englesbe M.J.
        • Holcombe S.
        • Wang S.
        Sarcopenia as a prognostic factor among patients with stage III melanoma.
        Ann Surg Oncol. 2011; 18: 3579-3585
        • Peng P.D.
        • van Vledder M.G.
        • Tsai S.
        • de Jong M.C.
        • Makary M.
        • Ng J.
        • et al.
        Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis.
        HPB (Oxford). 2011; 13: 439-446
        • Goodpaster B.H.
        • Kelley D.E.
        • Thaete F.L.
        • He J.
        • Ross R.
        Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content.
        J Appl Physiol (1985). 2000; 89: 104-110
        • Faul F.
        • Erdfelder E.
        • Lang A.G.
        • Buchner A.
        G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.
        Behav Res Methods. 2007; 39: 175-191
        • Faul F.
        • Erdfelder E.
        • Buchner A.
        • Lang A.G.
        Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.
        Behav Res Methods. 2009; 41: 1149-1160
        • Khuri S.F.
        • Daley J.
        • Henderson W.
        • Hur K.
        • Demakis J.
        • Aust J.B.
        • et al.
        The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program.
        Ann Surg. 1998; 228: 491-507
        • Ballehaninna U.K.
        • Chamberlain R.S.
        The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal.
        J Gastrointest Oncol. 2012; 3: 105-119
        • Tan B.H.
        • Birdsell L.A.
        • Martin L.
        • Baracos V.E.
        • Fearon K.C.
        Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.
        Clin Cancer Res. 2009; 15: 6973-6979
        • Cooper A.B.
        • Slack R.
        • Fogelman D.
        • Holmes H.M.
        • Petzel M.
        • Parker N.
        • et al.
        Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer.
        Ann Surg Oncol. 2015; 22: 2416-2423
        • Hasselager R.
        • Gogenur I.
        Core muscle size assessed by perioperative abdominal CT scan is related to mortality, postoperative complications, and hospitalization after major abdominal surgery: a systematic review.
        Langenbecks Arch Surg. 2014; 399: 287-295
        • Norton J.A.
        • Stein T.P.
        • Brennan M.F.
        Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer.
        Ann Surg. 1981; 194: 123-128
        • Delano M.J.
        • Moldawer L.L.
        The origins of cachexia in acute and chronic inflammatory diseases.
        Nutr Clin Pract. 2006; 21: 68-81